<p>Anavex Life Sciences Corp. is facing a regulatory setback in the European Union regarding its lead drug candidate, blarcamesine, for early Alzheimer’s disease. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the company’s marketing authorisation application after a trend-vote in November. Anavex plans to request a re-examination, which will be conducted by a new set of reviewers independent from the initial decision. The outcome of this process may impact the company’s ability to bring blarcamesine to market in the EU. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9601611-en) on December 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

AVXL

<p>The European Medicines Agency's CHMP rejected Anavex Life Sciences Corp.'s application for its Alzheimer's drug, blarcamesine, in the EU. Anavex plans to request a re-examination by independent reviewers, which could affect its market entry in the EU.</p>

EU Regulator Rejects Anavex Alzheimer's Drug Application